Bristol Myers and BioNTech form $11.1B partnership to co-develop next-generation cancer drug BNT327, aiming to accelerate trials and expand indications.
Supreme Court declines to hear challenges to Maryland and Rhode Island gun control laws, leaving restrictions on assault-style weapons and high-capacity magazines in place.
Bristol Myers and BioNTech form $11.1B partnership to co-develop next-generation cancer drug BNT327, aiming to accelerate trials and expand indications.
Supreme Court declines to hear challenges to Maryland and Rhode Island gun control laws, leaving restrictions on assault-style weapons and high-capacity magazines in place.